Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.25 Consensus PT from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.60.

ESPR has been the topic of several research reports. Piper Sandler began coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 price objective on the stock. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. Finally, Needham & Company LLC upped their price target on Esperion Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. DHJJ Financial Advisors Ltd. lifted its position in Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 6,380 shares during the period. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the 2nd quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $29,000. R Squared Ltd acquired a new position in shares of Esperion Therapeutics in the 3rd quarter valued at $33,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Esperion Therapeutics during the 4th quarter worth about $35,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Trading Up 0.7%

Shares of Esperion Therapeutics stock opened at $2.71 on Friday. The company’s fifty day simple moving average is $3.23 and its 200-day simple moving average is $3.16. The company has a market cap of $695.96 million, a price-to-earnings ratio of -15.94, a PEG ratio of 1.93 and a beta of 1.11. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million. As a group, research analysts forecast that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.